PCSK9 Inhibiting siRNA

Currently available therapies reduce low-density lipoprotein cholesterol (LDL-C) through a variety of mechanisms, with statins being the most widely utilized of all therapies. However, patients who do not respond to statin therapy or other oral agents, or who develop side effects from taking the medications often need novel treatments. Inclisiran is a new and novel small interfering RNA compound which inhibits the translation of mRNA for Proprotein convertase subtilisin-kexin 9 (PCSK9) and thus reduces plasma levels of LDL-C. This chapter will focus on small interfering RNA compound PCSK9 inhibitors, which is currently under active investigation, by discussing pharmacology, clinical trials with a focus on stroke outcomes, and clinical use in practice.